Breaking News: GRAIL’s Revolutionary Prognostic Test for Stage I Lung Cancer Unveiled at North America Conference on Lung Cancer
Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional Treatment MENLO PARK, Calif. & CAMBRIDGE, England & SEOUL, South Korea–(BUSINESS WIRE)– GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, highlighted the presentation of analytical and clinical…